News
ABMD
--
0.00%
--
Is Abiomed, Inc.'s(NASDAQ:ABMD) Recent Stock Performance Tethered To Its Strong Fundamentals?
Abiomed's (NASDAQ:ABMD) stock is up by a considerable 9.4% over the past month. Given the company's impressive...
Simply Wall St. · 13h ago
Abiomed Announces First Patient Enrolled In PROTECT IV Randomized Controlled Trial Of Impella
Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical
Benzinga · 1d ago
Abiomed Commences Enrollment for Impella Trial in High-Risk Percutaneous Coronary Intervention
MT Newswires · 1d ago
Chicago Capital, LLC Buys Lithia Motors Inc, Abiomed Inc, Ligand Pharmaceuticals Inc, Sells ...
GuruFocus News · 3d ago
Abiomed Inc. stock underperforms Monday when compared to competitors
Shares of Abiomed Inc. slumped 0.21% to $333.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...
marketwatch.com · 3d ago
Interventional Cardiology & Peripheral Vascular Devices Market Research Report by Trends, by Type, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 12, 2021 (Heraldkeepers) -- The Global Interventional Cardiology & Peripheral Vascular Devices Market is expected to exceed more than US$ 28 billion...
Heraldkeepers · 4d ago
Abiomed Inc. stock underperforms Friday when compared to competitors despite daily gains
Shares of Abiomed Inc. advanced 1.23% to $333.81 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
marketwatch.com · 6d ago
Outlook on the Artificial Organ and Bionics Global Market to 2025 - Competitive Analysis and Impact of COVID-19
Dublin, April 09, Apr 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 09, 2021 (GLOBE NEWSWIRE) -- The "Global Artificial Organ and Bionics Market...
GlobeNewswire · 04/09 12:14
Abiomed Stock Appears To Be Fairly Valued
GuruFocus News · 04/08 12:12
Cardiac Assist Devices Market Research Report by Device, by Service, by Industry – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 08, 2021 (Heraldkeepers) -- The Global Cardiac Assist Devices market is expected to grow at a CAGR of 10.02% during the projected period. Cardiac Assist...
Heraldkeepers · 04/08 11:53
Press Release: Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification
Dow Jones · 04/08 11:03
Abiomed Inc. stock falls Wednesday, underperforms market
Shares of Abiomed Inc. dropped 0.93% to $320.62 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
marketwatch.com · 04/07 20:33
Abiomed Inc. stock rises Tuesday, outperforms market
Shares of Abiomed Inc. inched 0.66% higher to $323.62 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...
marketwatch.com · 04/06 20:33
Abiomed Inc. stock outperforms competitors on strong trading day
Shares of Abiomed Inc. rallied 1.95% to $321.50 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...
marketwatch.com · 04/05 20:33
Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed
Zacks.com · 03/31 21:36
Abiomed Inc Down 2.9% Since SmarTrend Downtrend Call (ABMD)
Mar 30, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Abiomed Inc (NASDAQ:ABMD) on February 17th, 2021 at $317.58. In...
marketwatch.com · 03/30 18:05
3 Top Medical Instruments Stocks to Beat COVID-19 Resurgence Crisis
Zacks.com · 03/30 15:24
Webull provides a variety of real-time ABMD stock news. You can receive the latest news about Abiomed through multiple platforms. This information may help you make smarter investment decisions.
About ABMD
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.